Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.41 |
| ▸ | GABRD | O14764 | 5/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.41 |
| ▸ | GABRE | P78334 | 5/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.37 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.37 |
| ▸ | C1R | P00736 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489417 | 0.76 | ELANE (0.41) | PIK3CDPIK3CBALDH1A1ELANE | |
| SCHEMBL7488164 | 0.76 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2571683 | 0.76 | C1R (0.37) | C1RNPC1RAB9AELANEPSMB8 | |
| SCHEMBL5043562 | 0.76 | PSMB8 (0.56) | C1RNPC1RAB9AALDH1A1ELANE | |
| SCHEMBL9304178 | 0.76 | ACHE (0.43) | NPC1RAB9AALDH1A1MAPTNPSR1 | |
| SCHEMBL13279634 | 0.76 | RPS6KA2 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5544332 | 0.76 | ELANE (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1463176 | 0.76 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30618071 | 0.76 | RPS6KA2 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5544327 | 0.76 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0572893-A1 | Fluor-benzoxazolyloxyacetamides | BAYER AG (DE) | 1993-12-08 | — | — | EP | claimed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| CN-105431427-A | Novel PDE4 inhibitor | MEIJI SEIKA PHARMA CO LTD | 2016-03-23 | — | — | CN | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-0883611-B1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0883611-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-16 | — | — | EP | disclosed |
| US-5736545-A | ADMINISTERING TO TREAT BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997030981-A1 | AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0572893-A1 | Fluor-benzoxazolyloxyacetamides | BAYER AG (DE) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | GABRP 2813/4885GABRD 4231/4885GABRA1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.